BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 24, Issue 41
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (9370)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-1) series.
Item 
Count 
PDF753
HTML4644
Figures (1-1)566
 Sum=5963
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1337
Download2057
 Sum=3394
Nov 7, 2018 (publication date) through Feb 28, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2018; 24(41): 4617-4621
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4617
Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
Luigi Elio Adinolfi, Luca Rinaldi, Riccardo Nevola
Luigi Elio Adinolfi, Luca Rinaldi, Riccardo Nevola, Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania “L. Vanvitelli”, Naples 80138, Italy
Author contributions: Adinolfi LE conceived the editorial; all authors equally contributed to the realization of the editorial.
Conflict-of-interest statement: The authors state that they do not have any conflict of interest to declare.
Correspondence to: Luigi Elio Adinolfi, MD, Full Professor, Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania “L. Vanvitelli”, Piazza Miraglia, Naples 80138, Italy. luigielio.adinolfi@unicampania.it
Telephone: +39-81-5665081
Received: August 18, 2018
Peer-review started: August 19, 2018
First decision: October 9, 2018
Revised: October 11, 2018
Accepted: October 21, 2018
Article in press: October 21, 2018
Published online: November 7, 2018
Processing time: 81 Days and 7.8 Hours
Core Tip

Core tip: Chronic hepatitis C (HCV) infection is associated with an increased risk of atherosclerosis, cardiovascular disease and cardiovascular mortality. HCV lives within carotid plaques, promotes pro-atherogenic conditions such as pro-inflammatory cytokines, oxidative stress, insulin resistance, diabetes, steatosis, cryoglobulinemia and endotoxinemia. Direct-acting antiviral agents (DAA) are highly effective and safe therapeutic regimens. There are a number of studies showing that HCV clearance by DAAs is associated with an improvement in atherosclerosis and a reduced risk of cardiovascular events. In addition, HCV clearance is associated with improvement of metabolic and immunological conditions that promote cardiovascular disease. Further studies will be needed to confirm these promising data.
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345